Visible-Light Photoswitchable Benzimidazole Azo-Arenes as beta-Arrestin2-Biased Selective Cannabinoid 2 Receptor Agonists

  • Sophie A M Steinmueller
  • , Julia Fender
  • , Marie H Deventer
  • , Anna Tutov
  • , Kristina Lorenz
  • , Christophe P Stove
  • , James Hislop
  • , Michael Decker* (Corresponding Author)
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)
6 Downloads (Pure)

Abstract

The cannabinoid 2 receptor (CB2R) has high therapeutic potential for multiple pathogenic processes, such as neuroinflammation. Pathway-selective ligands are needed to overcome the lack of clinical success and to elucidate correlations between pathways and their respective therapeutic effects. Herein, we report the design and synthesis of a photoswitchable scaffold based on the privileged structure of benzimidazole and its application as a functionally selective CB2R "efficacy-switch". Benzimidazole azo-arenes offer huge potential for the broad extension of photopharmacology to a wide range of optically addressable biological targets. We used this scaffold to develop compound 10d, a "trans-on" agonist, which serves as a molecular probe to study the β-arrestin2 (βarr2) pathway at CB2R. βArr2 bias was observed in CB2R internalization and ßarr2 recruitment, while no activation occurred when looking at Gα16 or mini-Gαi. Overall, compound 10d is the first light-dependent functionally selective agonist to investigate the complex mechanisms of CB2R-βarr2 dependent endocytosis.

Original languageEnglish
Article numbere202306176
Number of pages11
JournalAngewandte Chemie International Edition
Volume62
Issue number49
Early online date13 Jul 2023
DOIs
Publication statusPublished - 4 Dec 2023

Bibliographical note

Acknowledgements
The authors would like to acknowledge Dr. Andrea Holme for excellent technical support and the Iain Fraser Cytometry Centre (University of Aberdeen) for providing access to their equipment. The authors would like to thank Dr. Matthias Scheiner for his contributions towards the development of the calcium mobilization assay and Dr. Valérie Jahns for her efforts towards faster automated analysis of the obtained results. Nick Verhavert is acknowledged for his assistance with the NanoBiT® assay. Diego Rodriguez-Soacha is acknowledged for establishing the rCB1R radioligand binding assay in our laboratory. Special thanks to Dr. Rangan Maitra and RTI International for providing the G16
coupled hCB1 and hCB2 CHO-K1 cell lines. The authors thank Nadine Yurdagül-Hemmrich and Annette Hannawacker for excellent technical support.

Data Availability Statement

The data that support the findings of this study are available in the Supporting Information of this article.

Funding

This project was funded by the German Research Foundation (Deutsche Forschungsgemeinschaft under DFG DE1546/10-1). J. N. Hislop’s financing support was given by NHS Grampian. The research visit of S. A. M. Steinmüller in Dr. Hislop’s laboratory was funded by the Elite Network of Bavaria (grant N° K-BM-2013-247). J. Fender and A. Tutov were supported by the International Doctoral Program “Receptor Dynamics” funded within the framework of the Elite Network of Bavaria (grant N° K-BM-2013- 247). M. H. Deventer was funded by the Research FoundationFlanders (FWO; grant 1S54521N).

FundersFunder number
German Research FoundationDFG DE1546/10-1
NHS Grampian
Elite Network of BavariaK-BM-2013-247
Research Foundation Flanders1S54521N

    Keywords

    • benzimidazoles
    • G protein-coupled receptor
    • optical control
    • photopharmacology
    • biased ligand

    Fingerprint

    Dive into the research topics of 'Visible-Light Photoswitchable Benzimidazole Azo-Arenes as beta-Arrestin2-Biased Selective Cannabinoid 2 Receptor Agonists'. Together they form a unique fingerprint.

    Cite this